Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone propionate
Drug ID BADD_D00947
Description Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Indications and Usage Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358].
Marketing Status approved
ATC Code R03BA05; R01AD08; D07AC17
DrugBank ID DB00588
KEGG ID D01708
MeSH ID D000068298
PubChem ID 444036
TTD Drug ID D0LC6K
NDC Product Code 81522-002; 22552-0043; 51927-0013; 0113-0028; 41163-023; 0135-0582; 55910-607; 63868-656; 69842-765; 70000-0110; 72559-002; 46439-8729; 51552-1310; 11822-0901; 0113-0285; 37808-340; 41520-553; 0173-0601; 0173-0720; 50594-319; 53002-1294; 53002-7691; 59310-505; 59310-515; 0363-0652; 63629-8662; 63629-8663; 66993-078; 68788-7788; 0054-3270; 0713-0631; 80267-000; 81522-005; 16812-005; 64918-1600; 11673-262; 0173-0602; 0173-0718; 49035-063; 50090-0934; 53943-006; 55910-773; 60505-6205; 0363-0881; 63629-8658; 63629-8659; 64525-8000; 66993-079; 68196-208; 68788-8446; 68788-9678; 68998-600; 72189-004; 63654-380; 63981-001; 68196-210; 69842-757; 71143-375; 81522-073; 38779-2760; 53873-078; 55018-301; 11673-388; 46122-684; 49035-362; 50090-6053; 53002-1310; 53002-7693; 55301-506; 59310-114; 59310-311; 60505-0829; 63187-638; 63187-959; 63868-400; 64024-007; 68788-6926; 69306-016; 69842-900; 0536-1373; 49076-5501; 52482-001; 64918-1700; 11673-103; 11822-1177; 30142-258; 30142-301; 0113-7117; 36800-222; 0363-0024; 64525-6560; 69168-380; 70000-0613; 79903-071; 52221-106; 36800-572; 41163-100; 41250-634; 45802-222; 50090-2880; 50383-968; 59310-525; 62011-0269; 0363-1205; 63187-957; 68071-2582; 68071-4868; 68462-427; 0536-1183; 71205-443; 72288-119; 80425-0263; 53873-079; 63190-0520; 64918-1118; 37835-997; 0173-0719; 49348-182; 50090-0916; 50090-6058; 53002-2294; 60432-264; 63187-021; 63187-806; 0363-5012; 63629-8660; 63629-8661; 66993-080; 68016-723; 69842-770; 70518-1655; 0713-0632; 15308-0200; 58175-0361; 21130-089; 37808-205; 45802-221; 50090-6055; 50383-700; 56062-107; 59310-200; 60505-0955; 68391-133; 69256-061; 69842-228; 72288-333; 76162-656; 76420-106; 80159-201; 50909-5175; 63379-001; 11673-220; 21130-122; 36800-128; 41520-703; 46122-386; 51672-4095; 67296-1463; 53104-7531; 65089-0033; 0135-0576; 0168-0332; 0173-0600; 45802-441; 49035-200; 50090-0968; 51316-074; 60429-195
UNII O2GMZ0LF5W
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C25H31F3O5S
CAS Registry Number 80474-14-2
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.0030.002525%
Hypertension24.08.02.0010.000461%
Hypertrichosis23.02.04.002--
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypogeusia17.02.07.004; 07.14.03.002--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000184%
Hypokalaemia14.05.03.0020.000184%
Hyponatraemia14.05.04.0020.000645%
Hypopituitarism05.03.02.0010.000276%
Hypopnoea22.02.01.0210.000184%Not Available
Hypothalamo-pituitary disorder05.03.04.0030.000276%Not Available
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.0030.000184%
Immune system disorder10.02.01.001--Not Available
Impetigo23.11.02.011; 11.01.12.006--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injection site erythema12.07.03.001; 08.02.03.001; 23.03.06.0150.000405%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.000405%Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.0130.000184%Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.0320.000184%Not Available
Injection site warmth12.07.03.036; 08.02.03.036--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury12.01.08.036; 19.12.01.0020.000184%Not Available
Intracranial pressure increased17.07.02.0020.000184%Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.0110.000498%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lacrimation increased06.08.02.004--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages